stockportfolio.pro
Stocks / DGX vs INCY
DGX vs INCY
Quest Diagnostics Incorporated and Incyte Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
DGX is the larger company ($21.9B vs $19.8B). On the fundamentals, INCY grows revenue faster (14.0% vs 3.2%); INCY earns a higher net margin (25.0% vs 9.0%); INCY has the stronger return on equity (24.9% vs 13.8%). Full numbers below — the stronger figure on each row is in green.
| Quest Diagnostics Incorporated (DGX) | Incyte Corporation (INCY) | |
|---|---|---|
| Market cap | $21.9B | $19.8B |
| Revenue (latest FY) | $11.04B | $5.14B |
| Net income (latest FY) | $992.00M | $1.29B |
| Revenue growth (5y CAGR) | 3.2% | 14.0% |
| Net margin | 9.0% | 25.0% |
| Return on equity | 13.8% | 24.9% |
| P/E ratio | 21.9 | 14.0 |
| Dividend yield | 1.7% | — |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | — |
Compare with another company:
See the full DGX vs INCY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DGX's full financials → Open INCY's full financials →More comparisons
Frequently asked questions
Which is bigger, DGX or INCY?
Quest Diagnostics Incorporated is larger by market capitalization — $21.9B versus $19.8B.
Which grows faster, DGX or INCY?
Over the last five fiscal years, Incyte Corporation grew revenue faster — 14.0%/yr versus 3.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.